Postmortem Findings in Etoricoxib Poisoning: Reporting of a Rare Case
DOI:
https://doi.org/10.37506/3rv85t64Keywords:
Etoricoxib poisoning, postmortem, toxicology, forensic, COX-2 inhibitor overdoseAbstract
This case report details the postmortem findings of a case of Etoricoxib poisoning. Etoricoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is commonly used for pain management in musculoskeletal disorders. It usually has significantly low gastrointestinal symptoms. It is reported to be associated with rare but serious adverse effects when ingested in excessive amounts. In the present case, there is a history of an accidental overdose of Etoricoxib, and the victim expired during treatment and was sent for autopsy, wherein a grossly icteric body, all organs congested with muddy-looking liver, and an enlarged heart with biventricular dilation were seen.
References
Takemoto JK, Reynolds JK, Remsberg CM, Vega-Villa KR, Davies NM. Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib. Clinical pharmacokinetics. 2008 Nov; 47:703-20.
Shetty U, Neema P, Muthu S, Bhojwani D, Muchhala S, Shetty UK, Neema PP, Muthu S, Bhojwani DG. Nationwide Etoricoxib Injection Clinical Experience (NICE): Real-World Evidence in Indian Patients. Cureus. 2024 Feb 11;16(2).
Patrignani P, Capone ML, Tacconelli S. Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. Expert Opinion on Pharmacotherapy. 2003 Feb 1;4(2):265-84.
Agrawal NG, Porras AG, Matthews CZ, Rose MJ, Woolf EJ, Musser BJ, Dynder AL, Mazina KE, Lasseter KC, Hunt TL, Schwartz JI. Single- and multiple‐dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase‐2, in man. The Journal of Clinical Pharmacology. 2003 Mar;43(3):268-76.
Reddy KSN, Murty OP. The essentials of forensic medicine & toxicology. 35th ed. New Delhi, India: Jaypee Brothers Medical; 2022. 24, General Considerations, p.388.
Rodrigues AD, Halpin RA, Geer LA, Cui D, Woolf EJ, Matthews CZ, Gottesdiener KM, Larson PJ, Lasseter KC, Agrawal NG. Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. Drug metabolism and disposition. 2003 Feb 1;31(2):224-32.
Schumacher Jr HR, Boice JA, Daikh DI, Mukhopadhyay S, Malmstrom K, Ng J, Tate GA, Molina J. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. Bmj. 2002 Jun 22;324(7352):1488-92.
Tripathy S, Dash SC. Etoricoxib-induced life-threatening hyperkalemia and acute kidney dysfunction against the background of telmisartan and a low-sodium diet. International journal of emergency medicine. 2010 Dec; 3:443-6.
Tripathy S, Dash SC. Etoricoxib-induced life-threatening hyperkalemia and acute kidney dysfunction against the background of telmisartan and a low-sodium diet. International journal of emergency medicine. 2010 Dec; 3:443-6.
10.Smirnov G, Terävä M, Tuomilehto H, Hujala K, Seppänen M, Kokki H. Etoricoxib for pain management during thyroid surgery–a prospective, placebo-controlled study. Otolaryngology—Head and Neck Surgery. 2008 Jan;138(1):92-7.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
https://creativecommons.org/licenses/by-nc/2.0/deed.en